Pentax Medical has today announced an asset purchase agreement with Merit Medical Systems for the acquisition of the C2 CryoBalloon technology.
The C2 CryoBalloon has been part of Pentax Medical’s therapeutic portfolio since 2017, offering a minimally invasive option to treat patients suffering from Barrett’s Esophagus and other gastrointestinal disorders. The minimally invasive device delivers controlled cryotherapy to ablate unwanted tissue while preserving surrounding structures. A press release made by the company states that, under Merit Medical’s stewardship, the technology is expected to reach new levels of adoption and impact, expanding access to care for patients suffering from chronic gastroesophageal reflux disease (GERD) and related conditions.
“C2 technology has been an exciting part of our innovation journey,” said Dominique Vincent, president of Pentax Medical. “We are proud of the clinical value it has delivered and are confident that Merit Medical, with its expanding footprint in upper gastrointestinal (GI) treatments and deep expertise in therapeutic endoscopy, is ideally positioned to unlock the full potential of C2. This transition allows Pentax Medical to refocus on our core strength—flexible reusable endoscopy—and continue delivering intuitive solutions that empower clinicians worldwide.”
Merit Medical will integrate the C2 CryoBalloon into its endoscopy portfolio. Over the coming months, product manufacturing will be transferred to Merit’s facility in South Jordan, USA.
